Marinus Pharmaceuticals, Inc. (MRNS) Thursday said the China National Medical Products Administration (NMPA) has approved ganaxolone for the treatment of epileptic seizures in patients two years of age and older with CDKL5 deficiency disorder (CDD).
CDD is a genetic disorder characterized by seizures beginning in infancy with severe neurodevelopmental impairment.
In 2022, Tenacia Biotechnology had secured rights to develop and commercialize ganaxolone in China, Hong Kong, Macau and Taiwan. In return Marinus will receive royalties and other milestone payments.
The approval is supported by data from Marinus' Phase 3 Marigold trial in CDD. In the study, patients treated with ganaxolone showed a 30.7 percent median reduction in 28-day major motor seizure frequency, compared to a 6.9 percent reduction for those receiving placebo, achieving the trial's primary endpoint.
Ganaxolone is already approved in the U.S., and European Union to treat seizures associated with CDD.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.